This brochure provides a detailed overview of our in vitro pharmacology platform, specifically designed to model the core neuropathological processes underlying psychiatric disorders. By integrating in vitro neuronal cultures, iPSC-derived brain organoids, and advanced functional readouts, we enable quantitative assessment of compound effects in vitro, effectively accelerating the transition from target identification to preclinical validation.

Key highlights covered in this brochure include:

Comprehensive In Vitro Model Portfolio

Our platform covers a broad spectrum of psychiatric indications, including depression, anxiety, and schizophrenia. These models are designed to address the key pathological features of psychiatric disorders.

• Depression Models: Validated systems focusing on core cellular and molecular pathways, suitable for high‑throughput screening.
• Anxiety Models: Corticosterone- and GABAergic-based challenges to quantify neuronal hyperexcitability and receptor dysfunction.
• Schizophrenia Models: Cell-based systems based on well-defined pathological features, supporting mechanistic studies and biomarker discovery.
• iPSC-Derived Brain Organoids: Region-specific models (cortical, hippocampal, midbrain) that recapitulate neural network dynamics and disease-relevant phenotypes.

Translational Relevance & Mechanistic Depth

Leveraging high-purity neuronal cultures, our models capture key aspects of synaptic function, neural network activity, and neuroinflammatory states.ntegration with electrophysiology and live-cell imaging enables direct, quantifiable assessment of compound effects at the cellular and molecular level, reducing reliance on indirect behavioral endpoints.

Efficient In Vitro Pharmacology Platform

Designed for early-stage drug development, our in vitro platform supports:

• High-Throughput Drug Screening: Rapid prioritization of lead compounds using iPSC-derived neuronal models.
• Mechanism Exploration: Analysis of genetic or pharmacological perturbations to elucidate pathogenic pathways.
• Biomarker Discovery: Comparative molecular profiling to identify novel disease biomarkers.

Tailored End-to-End Solutions

From validated cell models and customized model development to high‑throughput screening and mechanistic studies, we provide flexible, scalable solutions aligned with your specific research objectives.

Whether you are screening novel compounds, exploring disease mechanisms, or seeking robust in vitro models to support your pipeline, this brochure details how Ace Therapeutics can serve as a strategic partner in your psychiatric drug discovery efforts.

Download the brochure to explore our full in vitro model capabilities and discover how our platform can accelerate your next program.

You might be interested in...